Drug Profile

Research programme: hypercholesterolaemia therapeutics - PharmaMax

Alternative Names: CV-101; CV-102; CV-103

Latest Information Update: 29 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PharmaMax
Class Antihyperlipidaemics; Naphthalenes; Nicotinic acids; Peripheral vasodilators; Vitamins
Mechanism of Action Cholesterol inhibitors; HMG-CoA reductase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

29 Aug 2023 Discontinued - Preclinical for Hypercholesterolaemia in China (unspecified route) (PharmaMax pipeline, August 2023)
28 Feb 2020 No recent reports of development identified for preclinical development in Hypercholesterolaemia in China
22 Jan 2016 Preclinical trials in Hypercholesterolaemia in China (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com